DOFAMIN VA RETSEPTORLARINING KIMYOVIY TUZILISHI . DOMPERIDON:YANGI PERIFERIK DOPAMINE ANTOGONISTI VA UNING HOZIRGI KUNDAGI AHAMIYATI.
##semicolon##
dopamin, dopamin retseptorlari, D3 retseptori, neyrotransmitter, domperidon, periferik antagonist,tibbiy kimyo, farmakologik faollik ,kimyoviy tuzilish, sintez jarayoni, Parkinson kasalligi, shizofreniya.##article.abstract##
Maqolada dopamin molekulasining kimyoviy tuzilishi, uning markaziy va periferik retseptorlar bilan o‘zaro ta’siri tibbiy kimyo nuqtai nazaridan ko‘rib chiqiladi. Neyrotransmitter sifatida dopaminning fiziologik ahamiyati, ayniqsa D3 retseptoriga bog‘liq jarayonlar, shuningdek, ushbu retseptorlarga selektiv ta’sir ko‘rsatadigan domperidon birikmasining sintezi va farmakologik xususiyatlari tahlil
etiladi. Domperidonning antiemetik va prokinetik xususiyatlari, uning kimyoviy sintezi bosqichlari va klinik qo‘llanilishi haqidagi ilmiy ma’lumotlar asosida, mazkur preparatning amaliy tibbiyotdagi o‘rni yoritib berilgan.
##submission.citations##
1. Beaulieu J.M., Gainetdinov R.R. The physiology, signaling, and pharmacology of
dopamine receptors. Pharmacol Rev. 2011;63(1):182–217.2. Missale C., Nash S.R., Robinson S.W., Jaber M., Caron M.G. Dopamine receptors:
from structure to function. Physiol Rev. 1998;78(1):189–225.
3. Sharma A., Kaur G., Tiwari V. Domperidone: A novel dopamine antagonist. Int J
Pharm Sci Res. 2016;7(3):1000–1008.
4. Jost W.H. Gastrointestinal motility problems in Parkinson's disease: effects of
domperidone. Mov Disord. 1997;12(6):952–957.
5. Chivers M., Kavallaris M., Adhikari S. Dopamine and its role in neurological
disorders. Trends Neurosci. 2020;43(3):186–199.
6. Rocco A., Compare D., Angrisani D., Sanduzzi Zamparelli M., Nardone G.
Domperidone: clinical uses and risks. Curr Drug Saf. 2010;5(1):63–67.
7. Sibley D.R., Monsma F.J. Molecular biology of dopamine receptors. Trends
Pharmacol Sci. 1992;13:61–69.
8. Busto U., Sproule B., Knight K. Use of domperidone in the treatment of levodopa
induced nausea and vomiting. Clin Neuropharmacol. 2001;24(3):143–146.
9. Surmeier D.J., Ding J., Day M., Wang Z., Shen W. D1 and D2 dopamine-receptor
modulation of striatal glutamatergic signaling. Trends Neurosci. 2007;30(5):228–235.
10. Pandey G.N. Role of dopamine and serotonin in neuropsychiatric diseases.
Neuropsychopharmacology. 2019;44(1):150–165.
